South Korea has ambitions to become a global COVID-19 vaccine production hub and one of the top five manufacturing bases by 2025.
The Asian country has stepped up its effort with the formation of the K-mRNA consortium, which paves the way for entering the homegrown mRNA vaccine race for COVID-19.
Data and analytics company GlobalData agrees that these initiatives will make South Korea competitive on a global stage.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze